Longeveron Inc. (LGVN) has completed full enrollment in its Phase 2b clinical trial for laromestrocel, targeting Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric and orphan-designated disease.
Top-line results are expected in the third quarter of 2026. These will follow the final 12-month follow-up.
Nataliya Agafonova, M.D., Chief Medical Officer of Longeveron, highlighted the enrollment milestone as a key step toward a potential new treatment for HLHS.
